Keywords
Rituximab
Idiopathic Thrombocytopenia
Treatment
Neurology
How to Cite
Abstract
This study aimed to present the case of rituximab in the treatment of a patient with multiple sclerosis, providing preliminary evidence of its efficacy. This case study included a review of the patient's medical records and an analysis of scientific literature from databases such as PubMed, Google Scholar, and SciELO. The results demonstrated a significant reduction in disease exacerbations and an improvement in the progression of functional disability. Although adverse events were reported, they were successfully managed with premedication. The conclusion is that rituximab may be a promising therapeutic option for refractory cases of multiple sclerosis, although prospective studies are needed to confirm these results.
References
Brancati S, Gozzo L, Longo L, Vitale DC, Drago F. Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval? Front Immunol. 2021 Jul 6;12:661882. doi: 10.3389/fimmu.2021.661882
Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One. 2013 Jul 2;8(7):e66308. doi: 10.1371/journal.pone.0066308
Castro-Macías JI, Rodríguez-Jiménez JC, Mena-Novoa A. Rituximab in the treatment of multiple sclerosis. Experience of a tertiary care hospital in Mexico. Gac Med Mex. 2023;159(3):180-184. English. doi: 10.24875/GMM.M23000769
Cerqueira JJ, Compston DAS, Geraldes R, Rosa MM, Schmierer K, Thompson A, Tinelli M, Palace J. Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis? J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):844-850. doi: 10.1136/jnnp-2017-317509
Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple sclerosis: a review. J Neurol. 2022 Jan;269(1):159-183. doi: 10.1007/s00415-020-10362-z
Petersen-Cherubini CL, Liu Y, Deffenbaugh JL, Murphy SP, Xin M, Rau CN, Yang Y, Lovett-Racke AE. Dysregulated autotaxin expression by T cells in multiple sclerosis. J Neuroimmunol. 2024 Feb 15;387:578282. doi: 10.1016/j.jneuroim.2023.578282
Claverie R, Perriguey M, Rico A, Boutiere C, Demortiere S, Durozard P, Hilezian F, Dubrou C, Vely F, Pelletier J, Audoin B, Maarouf A. Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing? Neurol Neuroimmunol Neuroinflamm. 2023 Aug 21;10(5):e200152. doi: 10.1212/NXI.0000000000200152
Xiao Z, Murakhovskaya I. Rituximab resistance in ITP and beyond. Front Immunol. 2023 Jul 28;14:1215216. doi: 10.3389/fimmu.2023.1215216
Zhong M, van der Walt A, Campagna MP, Stankovich J, Butzkueven H, Jokubaitis V. The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis. Neurotherapeutics. 2020 Oct;17(4):1768-1784. doi: 10.1007/s13311-020-00950-2
Langer-Gould A, Li BH, Smith JB, Xu S. Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections. Neurol Neuroimmunol Neuroinflamm. 2024 May;11(3):e200211. doi: 10.1212/NXI.0000000000200211
Godeau B. Purpura thrombopénique immunologique: physiopathologie et traitement [Immune thrombocytopenic purpura: pathophysiology and treatment]. Transfus Clin Biol. 2009 May;16(2):101-5. French. doi: 10.1016/j.tracli.2009.03.012
Piehl F, Alping P, Virtanen S, Englund S, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Mellergård J, Nilsson P, Olsson T, Salzer J, Svenningsson A, Frisell T. COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab. Ann Neurol. 2024 Jun 25. doi: 10.1002/ana.27012
Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 Sep;7(9):1466-1476. doi: 10.1002/acn3.51111
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Global Academic Nursing Journal